{"@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [{"@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.patentleaderboard.com/"}, {"@type": "ListItem", "position": 2, "name": "CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies", "item": "https://www.patentleaderboard.com/patent/6410319"}]}
Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies

CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies

US Patent 6410319 · Granted Jun 25, 2002

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Truncated epiderimal growth factor receptor (EGFRt) for transduced t cell select2025
Fluorescein-specific cars exhibiting optimal t cell function against FL-PLE labe2025
Methods of use for CAR T cells2025
Production of engineered T-cells by sleeping beauty transposon coupled with meth2025
Sequencing method for CAR T cell therapy2025
Bispecific or-gate chimeric antigen receptor responsive to CD20 and CD192025
Bispecific OR-gate chimeric antigen receptor responsive to CD20 and CD192025
Drug regulated transgene expression2025
Closed-system manufacturing process for CAR-T cells2024
Methods and compositions comprising B7H3 chimeric antigen receptors2024
Nucleic acids encoding IL-13 receptor alpha 2 (IL13Ra2) chimeric antigen recepto2024
Early intervention methods to prevent or ameliorate toxicity2024